Financial Performance - Bristol Myers Squibb reported quarterly earnings of $1.80 per share, exceeding the Zacks Consensus Estimate of $1.51 per share, compared to a loss of $4.40 per share a year ago, representing an earnings surprise of 19.21% [1] - The company posted revenues of $11.2 billion for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 4.38%, although this is a decrease from year-ago revenues of $11.87 billion [2] - Over the last four quarters, Bristol Myers has consistently surpassed consensus EPS estimates and revenue estimates [2] Stock Performance and Outlook - Bristol Myers shares have declined approximately 14.2% since the beginning of the year, while the S&P 500 has decreased by 8.6% [3] - The company's future stock performance will largely depend on management's commentary during the earnings call and the sustainability of the recent earnings numbers [3][4] - The current consensus EPS estimate for the upcoming quarter is $1.69 on revenues of $11.35 billion, and for the current fiscal year, it is $6.76 on revenues of $45.82 billion [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Bristol Myers belongs, is currently ranked in the top 32% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Exhibit 99.1 Bristol Myers Squibb Reports First Quarter Financial Results for 2025 Results Reflect Continued Growth Portfolio Momentum and Disciplined Execution (PRINCETON, N.J., April 24, 2025) – Bristol Myers Squibb (NYSE: BMY) today reports results for the first quarter of 2025. "Our strong execution in the first quarter drove continued momentum across our Growth Portfolio and meaningful progress in the pipeline," said Christopher Boerner, Ph.D., board chair and chief executive officer, Bristol Myers Squ ...

百时美施贵宝预计全年调整后每股收益6.70美元至7美元，此前预计6.55美元至6.85美元。 ...

Core Viewpoint - Bristol Myers Squibb exceeded first-quarter estimates and raised its revenue and profit guidance for the year, driven by cost-cutting measures and strong performance in its drug portfolio [1][4]. Financial Performance - The company reported a net income of $2.5 billion, or $1.20 per share, for the first quarter, a significant recovery from a net loss of $11.9 billion, or a loss of $5.89 per share, in the same period last year [6]. - Adjusted earnings per share were $1.80, surpassing the expected $1.49, while revenue was $11.2 billion, exceeding the anticipated $10.7 billion [10]. - Revenue from the growth portfolio reached $5.56 billion, marking a 16% increase from the previous year [11]. Revenue Guidance - The company now anticipates 2025 revenue between $45.8 billion and $46.8 billion, an increase from the prior estimate of around $45.5 billion [2]. - Full-year adjusted earnings are expected to be between $6.70 and $7 per share, up from the previous forecast of $6.55 to $6.85 per share [2]. Market Strategy - China is identified as a critical market, with the "China 2030 Strategy" aimed at addressing unmet medical needs and increasing participation in clinical trials [4]. - The guidance revisions consider the impact of current tariffs on U.S. products shipped to China but do not include potential tariffs on pharmaceuticals imported into the U.S. [3]. Cost-Cutting Initiatives - The company is implementing a plan to reduce expenses by $2 billion by the end of 2027, in addition to $1.5 billion in planned cuts by the end of this year [5]. Product Performance - Sales of Eliquis, a top-selling blood thinner, were $3.57 billion for the quarter, down 4% year-over-year but above analyst expectations [7]. - Opdivo generated $2.27 billion in revenue, a 9% increase from the previous year, also exceeding estimates [11]. - Cobenfy, a recently approved schizophrenia drug, generated $27 million in sales for the first quarter, following disappointing clinical trial results [5][11].

Core Insights - Zacks Premium provides tools for investors to enhance their stock market strategies and confidence, including daily updates, research reports, and stock screens [1] - The Zacks Style Scores are designed to rate stocks based on value, growth, and momentum, serving as complementary indicators to the Zacks Rank [2] Zacks Style Scores - Each stock receives a rating from A to F based on its value, growth, and momentum characteristics, with higher scores indicating a better chance of outperforming the market [3] - The Value Score identifies attractive and discounted stocks using various financial ratios, appealing to value investors [4] - The Growth Score focuses on a company's future prospects and financial health, analyzing earnings, sales, and cash flow for sustainable growth [5] - The Momentum Score helps investors capitalize on price trends by assessing recent price changes and earnings estimate revisions [6] - The VGM Score combines all three Style Scores, providing a comprehensive indicator for investors seeking the best value, growth, and momentum [6] Zacks Rank - The Zacks Rank is a proprietary model that utilizes earnings estimate revisions to assist investors in building successful portfolios [7] - Stocks rated 1 (Strong Buy) have historically achieved an average annual return of +25.41% since 1988, significantly outperforming the S&P 500 [8] - Investors are encouraged to select stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B for optimal investment potential [9] Stock Analysis: Bristol Myers Squibb (BMY) - Bristol Myers Squibb is a leading biopharmaceutical company focused on treatments for severe diseases, with notable products like Opdivo and a diverse portfolio including immunology and cardiovascular drugs [11] - BMY holds a 3 (Hold) rating on the Zacks Rank, with a VGM Score of A and a Value Style Score of B, indicating attractive valuation metrics such as a forward P/E ratio of 7.23 [12] - Recent upward revisions in earnings estimates and a Zacks Consensus Estimate of $6.77 per share for fiscal 2025, along with an average earnings surprise of 16.2%, make BMY a stock of interest for investors [12][13]

Core Insights - The Medical sector's first-quarter 2025 earnings season is gaining momentum, with strong initial results from Johnson & Johnson, which exceeded earnings and sales estimates and raised its sales guidance for the year [1] - As of April 16, 3.3% of Medical sector companies reported earnings, with 100% surpassing earnings estimates and 50% exceeding revenue estimates, indicating a positive trend for the sector [1] - Overall, first-quarter earnings for the Medical sector are projected to increase by 34.7%, while sales are expected to rise by 7.5% compared to the previous year [1] Gilead Sciences - Gilead Sciences has a strong earnings track record, beating estimates in the last four quarters with an average surprise of 19.47% [3] - For Q1 2025, Gilead has an Earnings ESP of +3.07% and a Zacks Rank of 3, with consensus earnings estimated at $1.73 per share [5] - The company's revenue is expected to be supported by its HIV therapies, although it may face challenges due to the new Medicare Part D model affecting discounts [6][7] Bristol Myers - Bristol Myers has also shown a solid earnings performance, beating estimates in the last four quarters with an average surprise of 16.18% [8] - For the upcoming quarter, Bristol Myers has an Earnings ESP of -0.51% and a Zacks Rank of 3, with consensus earnings estimated at $1.54 per share [8] - Revenue is anticipated to be impacted by declining sales from legacy drugs, but this may be offset by growth in newer products [9] Merck - Merck has a favorable earnings history, beating estimates in the last four quarters with an average surprise of 4.68% [11] - For Q1 2025, Merck has an Earnings ESP of -2.04% and a Zacks Rank of 3, with consensus earnings estimated at $2.16 per share [11] - Revenue growth is expected to be driven by the strong performance of its cancer drug Keytruda, although international sales of the HPV vaccine Gardasil may be negatively affected [12] AbbVie - AbbVie has consistently beaten earnings estimates, with an average surprise of 2.37% over the last four quarters [13] - For the upcoming quarter, AbbVie has an Earnings ESP of -3.61% and a Zacks Rank of 3, with consensus earnings estimated at $2.47 per share [13] - The company's revenue is likely to be bolstered by strong sales of key drugs and contributions from newer products [14] Sanofi - Sanofi has a mixed earnings record, beating estimates in two of the last four quarters, with an average surprise of 5.14% [15] - For Q1 2025, Sanofi has an Earnings ESP of +1.62% and a Zacks Rank of 3, with consensus earnings estimated at 90 cents per share [15] - Revenue is expected to benefit from higher sales of Dupixent and new products, although lower flu vaccine sales and generic competition may pose challenges [16]

I may purchase a long position in BMY over the next 72 hours. All opinions expressed herein are not investment recommendations and are not meant to be relied upon in investment decisions. The author is not acting in an investment advisor capacity and is not a registered investment advisor. The author recommends investors consult a qualified investment advisor before making any trade. Any projections, market outlooks, or estimates herein are forward-looking statements based upon certain assumptions that shou ...

Core Viewpoint - Bristol Myers Squibb (BMY) is expected to report a significant increase in quarterly earnings per share, while revenues are projected to decline year-over-year [1]. Financial Projections - Analysts predict quarterly earnings of $1.54 per share, reflecting a 135% increase compared to the same period last year [1]. - Revenues are forecasted to be $10.74 billion, representing a year-over-year decrease of 9.5% [1]. - The consensus EPS estimate has been adjusted upward by 0.8% over the past 30 days, indicating a reassessment of initial projections by analysts [2]. Key Metrics Estimates - Net Sales for Recent LOE Products - Revlimid is estimated at $879.35 million, indicating a change of -47.3% from the prior-year quarter [5]. - Net Sales for In-Line Products - Opdivo is expected to reach $2.18 billion, reflecting a year-over-year change of +4.9% [5]. - Net Sales for Recent LOE Products - Abraxane is projected at $127.62 million, showing a change of -41.2% from the year-ago quarter [6]. - Net Sales for New Product Portfolio - Reblozyl is estimated at $483.40 million, indicating a change of +36.6% year-over-year [6]. - Net Sales for Recent LOE Products - Abraxane (U.S.) is expected to be $66.33 million, reflecting a year-over-year change of -54.3% [7]. - Net Sales for In-Line Products - Opdivo (U.S.) is projected at $1.19 billion, indicating a year-over-year change of +3.4% [7]. - Net Sales for In-Line Products - Pomalyst/Imnovid (U.S.) is expected to reach $582.15 million, reflecting a change of -2.5% from the prior-year quarter [8]. - Net Sales for Recent LOE Products - Revlimid (U.S.) is estimated at $706.32 million, indicating a change of -51.4% from the prior-year quarter [9]. - Net Sales for New Product Portfolio - Reblozyl (U.S.) is projected at $392.41 million, reflecting a change of +33.9% from the prior-year quarter [10]. Market Performance - Over the past month, Bristol Myers shares have recorded returns of -18.5%, compared to the Zacks S&P 500 composite's -6.9% change [10]. - Based on its Zacks Rank 3 (Hold), BMY is expected to perform in line with the overall market in the upcoming period [10].

Biotech giant Bristol-Myers Squibb Company (BMY) is scheduled to report first-quarter 2025 results on April 24, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $10.74 billion and $1.54 per share, respectively.Earnings estimate for 2025 has increased to $6.78 from $6.75 per share over the past 30 days, while that for 2026 has decreased to $6.06 from $6.08. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)Image Source: Zacks Investment ResearchBMY’s ...

Core Viewpoint - Gilead Sciences, Inc. (GILD) and Bristol Myers Squibb (BMY) are prominent biotechnology companies with diverse portfolios and global reach, each presenting unique investment opportunities and challenges [1][2][3]. Gilead Sciences (GILD) - Gilead is a leader in the HIV treatment market, with its flagship drug Biktarvy being the most prescribed regimen for HIV-1 infection, maintaining a growing market share [4]. - The company’s prevention drug, Descovy, holds over 40% market share in the U.S. for pre-exposure prophylaxis (PrEP) [4]. - Late-stage studies for lenacapavir, a potential twice-yearly HIV prevention treatment, could significantly enhance Gilead's HIV portfolio [5]. - Gilead's oncology segment includes the successful breast cancer drug Trodelvy, which is undergoing further label expansion studies [6]. - The liver disease portfolio has been bolstered by the FDA approval of seladelpar for primary biliary cholangitis, enhancing Gilead's offerings in this area [7]. - As of December 31, 2024, Gilead's total debt-to-total-capital ratio was 59%, with $10 billion in cash and long-term debt of $25 billion [8]. Bristol Myers Squibb (BMY) - BMY's Growth Portfolio, including drugs like Reblozyl and Opdualag, has stabilized revenue amidst generic competition, with Reblozyl showing strong performance [9][10]. - Opdivo continues to gain momentum with consistent label expansions, and the recent FDA approval for subcutaneous use is expected to enhance its immuno-oncology franchise [11]. - BMY has made strategic acquisitions to expand its portfolio, including the recent approval of Cobenfy for schizophrenia, validating its acquisition strategy [12]. - Despite the growth from newer drugs, BMY faces challenges from generic competition affecting legacy drugs, which significantly impact revenue [13]. - As of December 31, 2024, BMY's total debt-to-total-capital ratio was 75.2%, with cash and equivalents of $10.3 billion and long-term debt of $47.6 billion [14]. Financial Estimates and Performance - The Zacks Consensus Estimate for GILD's 2025 sales indicates a slight decrease of 0.39%, while EPS is expected to increase by 70.13% [15]. - In contrast, BMY's 2025 sales are projected to decrease by 5.11%, but EPS is anticipated to rise by 489.57% [18]. - GILD has outperformed BMY in price performance, with a gain of 15.2% compared to BMY's loss of 9.6% year-to-date [22]. - Valuation metrics show GILD trading at a forward P/E ratio of 13.23, higher than BMY's 7.61 [22]. - BMY offers a higher dividend yield of 4.83% compared to GILD's 2.97% [24]. Investment Outlook - Gilead's innovation in its HIV portfolio and potential approval of lenacapavir for HIV prevention are seen as strong growth catalysts [25]. - BMY's efforts to counteract generic competition are noted, but the outlook for 2025 appears challenging [26]. - Overall, GILD is considered a more favorable investment option at present due to its solid fundamentals and growth potential despite its higher valuation [26].